American Society of Clinical Oncology (ASCO) Publishes Abstract of SIRveNIB, an Investigator-led Asia Pacific Primary Liver Cancer S

Publicado 18/05/2017 16:42:37CET

[1] Intent-to-treat group includes all patients who were enrolled and randomly allocated to treatment and are analysed according to the group to which they were randomized.  The intent-to-treat-group included n=182 (Y-90 resin microspheres) and n=178 (sorafenib).

[2] Treated group includes only those patients who completed the treatment originally allocated.  The treated group included n=130 (Y-90 resin microspheres) and n=162 (sorafenib).

[3] Ferlay J et al.  Globocan 2012. v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: , accessed on 18/May/2017.

[4] EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma.  J Hepatol 2012; 56: 908-43.


CONTACT: For media enquiries, please contact: National Cancer CentreSingapore, Ms Rachel Tan, Assistant Manager, Corporate Communications, Tel:+65 6236 9535 , Hp: 9754 0842 Email: , MsGillian Tan Senior Executive, Corporate Communications , Tel: +65 6236 9529Hp: 8157 3671, Email:

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación

Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies